Natalizumab use during the third trimester of pregnancy

JAMA Neurology

Volumn 71, Issue 7, 2014, Pages 891-895

  Haghikia, Aiden ^a   Langer Gould, Annette ^b   Rellensmann, Georg ^c   Schneider, Henriette ^d   Tenenbaum, Tobias ^d   Elias Hamp, Birte ^e   Menck, Sylvia ^f   Zimmermann, Julian ^g   Herbstritt, Sandra ^h   Marziniak, Martin ⁱ   Kum̈pfel, Tania ^j   Meinl, Ingrid ^j   Plavina, Tatiana ^k   Gold, Ralf ^a   Hellwig, Kerstin ^a,b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Department of Research and Evaluation Kaiser Permanente Southern California ^*  (United States)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Neurological Outpatient Practice   (Germany)

^f Neurology Outpatient Center Barsinghausen   (Germany)

^g UNIVERSITY OF BONN   (Germany)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ KLINIKUM MÜNCHEN OST   (Germany)

^j UNIVERSITY OF MUNICH   (Germany)

^k BIOGEN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANEMIA, NEONATAL; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FETAL BLOOD; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LEUKOCYTOSIS; MULTIPLE SCLEROSIS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY TRIMESTER, THIRD; THROMBOCYTOPENIA;

EID: 84905454867     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.209     Document Type: Article

References (20)

1. Haghikia A, Hohlfeld R, Gold R, Fugger L. Therapies for multiple sclerosis: translational achievements and outstanding needs. Trends Mol Med. 2013;19(5):309-319.
2. Rigau V, Mania A, Béfort P, et al. Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology. 2012;79(22):2214-2216.
3. Hellwig K, Gold R. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology. 2011;76(15):1362-1363, author reply 1363.
4. Lenhard T, Biller A, Mueller W, Metz I, Schönberger J, Wildemann B. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology. 2010;75(9):831-833.
5. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T; Pregnancy in Multiple Sclerosis Group. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med. 1998;339(5):285-291. (Pubitemid 28366416)
6. Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord. 2012;5(5):247-253.
7. Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17(8):958-963.
8. Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86(2):144-156.
9. Schneider H, Miller RK. Receptor-mediated uptake and transport of macromolecules in the human placenta. Int J Dev Biol. 2010;54(2-3):367-375.
10. Henderson CE. Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis. Acta Neurol Scand. 2012;126(1):e7.
11. Hoevenaren IA, de Vries LC, Rijnders RJ, Lotgering FK. Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases. Acta Neurol Scand. 2011;123(6):430-433.
12. Schneider H, Weber CE, Hellwig K, Schroten H, Tenenbaum T. Natalizumab treatment during pregnancy: effects on the neonatal immune system. Acta Neurol Scand. 2012;127(1):e1-e4.
13. Wehner NG, Shopp G, Oneda S, Clarke J. Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86(2):117-130.
14. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286-292; quiz e224.
15. Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol. 2011;258(9):1665-1669.
16. Borriello G, Prosperini L, Mancinelli C, Gianni C, Fubelli F, Pozzilli C. Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study. Eur J Neurol. 2012;19(5):783-787.
17. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130-1135.
18. Khan AARA, Rodriguez A, Kaakinen M, Pouta A, Hartikainen AL, Jarvelin MR. Does in utero exposure to synthetic glucocorticoids influence birthweight, head circumference and birth length? a systematic review of current evidence in humans. Paediatr Perinat Epidemiol. 2011;25(1):20-36.
19. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385-392.
20. Gelineau-van Waes J, Rainey MA, Maddox JR, et al. Increased sphingoid base-1-phosphates and failure of neural tube closure after exposure to fumonisin or FTY720. Birth Defects Res A Clin Mol Teratol. 2012;94(10):790-803.